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Objective: The antioxidant activity of vitamin E is derived primarily from alpha-tocopherol (α-T) and gamma-
tocopherol (γ-T). Results of epidemiological studies have demonstrated an inverse relationship between vitamin 
E intake and coronary disease. However, the results of clinical trials using α-T are equivocal. We determined the 
effect of 5 weeks of 100 mg/d or 200 mg/d γ-T supplementation on thrombotic markers such as platelet reactiv-
ity, lipid profile and the inflammation marker C-reactive protein (CRP). 
Methods and results: Fourteen healthy subjects consumed 100 mg/day while 13 consumed 200 mg/d of γ-T and 
12 received placebo (soybean capsules with less than 5 mg/d γ-T) in a double-blinded parallel study design. Fast-
ing pre and post dose blood samples were analysed. Blood γ-T concentrations increased significantly (p<0.05) 
relative to dose during the intervention period. Both groups receiving active ingredients showed significantly 
lower platelet activation after supplementation (p<0.05). Subjects consuming 100 mg/d γ-T had significantly de-
creased LDL cholesterol, platelet aggregation and mean platelet volume (MPV) (p<0.05). Little effect of γ-T was 
observed on other parameters. 
Conclusions: These data suggest that γ-T supplementation may have a permissive role in decreasing the risk of 
thrombotic events by improving lipid profile and reducing platelet activity. 
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INTRODUCTION  
Vitamin E is an essential nutrient, the main lipid soluble 
antioxidant, and plays a significant role in protecting bio-
logical membranes and lipoproteins from oxidative damage 
caused by free radicals.1-3 Vitamin E is not a single com-
pound with at least four tocopherols (α, β, δ and γ-
tocopherol) and four tocotrienols (α, β, δ and γ-tocotrienol) 
known.4 The antioxidant activity of vitamin E is derived 
primarily from α-tocopherol and γ-tocopherol, of which α-
tocopherol is most biologically active and the predominant 
form found in blood. In contrast, the predominant form of 
vitamin E found in food is γ–tocopherol.5 The dietary 
intake of γ-tocopherol is at least two times that of α-
tocopherol in Western diets, while the concentrations of α-
tocopherol in human blood are generally four times higher 
than those of γ-tocopherol.5   
  An inverse relationship has been found between acute 
coronary events and antioxidant vitamin E intake. For 
example, epidemiological studies have shown that vitamin 
E (α-T and γ-T) is associated with reduced number of 
ischemic cardiac events in patients with documented coro-
nary artery disease.6 Tocotrienols have also been shown to 
be beneficial by attenuating the formation of atheroscle-
rotic lesions and decreasing serum cholesterol effects in 
animal and in vitro studies but results in humans have been 
inconclusive. 7-9 The results of large clinical trials examin-
ing effect of Vitamin E (tocopherols) on cardiovascular 
diseases have been equivocal.10 Supplementation with large 
amounts of α-tocopherol (1,200 IU per day) has been 
shown to decrease blood concentrations of γ-tocopherol.11 
Gamma tocopherol has been found to be more effective 
than mixed tocopherol in protecting against certain specific 
types of oxidative damage. 
  Saldeen et al 12-13 showed an antithrombotic effect of 
vitamin E (γ-T and α-T) on thrombus formation, with more 
pronounced effect with gamma-tocopherol. These workers 
also demonstrated that platelet aggregation was inhibited 
more potently with a mixed tocopherol preparation (100 
mg γ-tocopherol, 40 mg δ-tocopherol, and 20 mg α-
tocopherol) than with α-tocopherol alone and attributed this 
observation to increased nitric oxide (NO) release, endothe-
lial constitutive nitric-oxide synthase (ecNOS) activation, 
and superoxide dismutase (SOD) protein content in plate-
lets in response to mixed tocopherol.13 
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In a placebo controlled double-blind study, we deter-
mined the effect of 5 wk of supplementation with γ-T at 
different doses (100 mg/d or 200 mg/d) on thrombotic 
risk factors, including platelet aggregation and activation. 
The effect of supplementation on plasma lipids and in-
flammation marker CRP was also investigated. 
 
MATERIALS AND METHODS 
Subjects and dietary intake 
After obtaining approval from RMIT Human Research 
Ethics Committee, 42 healthy volunteers were recruited. 
All the subjects were between 20 to 40 years old with no 
known medical history. None were on any form of medi-
cation for the duration of the study. Exclusion criteria 
included heavy drinking, smoking, and taking anti-
inflammatory medication and antioxidant supplements or 
antioxidant rich food interfering with platelet function in 
the 2 wk prior to study entry. None of the subjects had a 
history of bleeding disorders, diseases of the circulatory 
system or diabetes. Two subjects withdrew from the study 
due to time constraints while one subject was withdrawn 
due to difficulty in phlebotomy. No subjects used any 
platelet inhibitors during study.  
     Dietary γ-tocopherol supplementation was achieved 
through consumption of tablets after signed informed 
consent was obtained from all participants. The subjects 
were separated into 3 groups and randomly assigned to 
one of the treatment or placebo groups. Fourteen healthy 
subjects (7 male and 7 female) consumed 100 mg/day of 
γ-T while 13 (7 male and 6 female) consumed 200 mg/d 
of γ-T and 12 (5 male and 7 female) received colour and 
flavour-matched placebo (soybean capsules with less than 
5 mg/d γ-T) for 5 wks.  Tama Biochemical Company Ltd 
Japan supplied all γ-tocopherol and placebo capsules. 
    Subjects were required to complete a food frequency 
questionnaire over a 7-day period before commencing 
dietary supplementation, to confirm study participants 
were not consuming antioxidant rich foods or antioxidant 
supplements. 
    Fasting blood samples were collected for baseline as-
sessment prior to the study and after 5 wks of supplemen-
tation. All the procedures were followed in accordance 
with RMIT HREC guidelines. 
 
Experimental Trial 
On the morning of an experiment subjects reported to the 
laboratory between 0700-0800 h after a 12-14 h overnight 
fast. A resting blood sample was obtained for total plate-
let count, whole blood platelet aggregation, ATP release 
from platelet granules, mean platelet volume (MPV), flow 
cytometry for platelet activation marker, total cholesterol, 
high density lipoprotein (HDL) cholesterol, low density 
lipoprotein (LDL) cholesterol and triacylglycerols. CRP 
and serum α- & γ-tocopherol concentrations were also 
evaluated. 
 
Laboratory methods 
Blood collection. A total of 20 mL of venous blood was 
collected using a vacutainer adapter and 21 gauge 
vacuettes (Greiner bio-one GmbH, Kremsmünster, Aus-
tria) on two occasions. Blood was collected into 2 mL tri-
potassium ethylene-diamine-tetra acetic acid EDTA 
(1.8mg/mL), 8 mL tri-sodium citrate (3.8%) and 10 mL 
SST (serum separator tubes) tubes (Greiner bio-one 
GmbH, Kremsmünster, Austria). The EDTA tube was 
collected before the tri-sodium citrate tube to avoid col-
lecting platelets activated by venipuncture. Care was 
taken to ensure minimal specimen handling and agitation. 
All blood samples collected were tested according to the 
protocols described subsequently. 
 
Platelet function tests. Platelet count and MPV were 
measured by using whole blood collected in EDTA-
containing tubes with the use of a Beckman Coulter Ac.T 
5diff CP analyser (Coulter Corporation, Miami, FL, 
USA). Performance of the analyser was validated using 
Coulter Calibrator and Controls Plus.  
    Whole blood platelet aggregation was measured with 
an impedance aggregometer (Chrono-Log Corp, Philadel-
phia) equipped with MacLab software (ADInstruments 
Pty, Ltd, Castle Hill, Australia) for data quantitation and 
analysis. This method has been described previously.14 
Calibrations for impedance and ATP release were per-
formed daily before analysing blood samples. Briefly 
citrated whole blood was diluted with saline (1:1), 100 uL 
chrono-Lume reagent was added, sample was then incu-
bated, and mixed with agonists 2 µg collagen/mL 
[Chrono-Log Corp] [1 mmol arachidonic acid (AA)/L 
was used to stimulate platelets for repeating the aggrega-
tion as a check for anti-inflammatory intake], and aggre-
gation was recorded for 6 min. ATP release from platelets 
reacted with luciferin-luciferase in the Chrono-Lume re-
agent and luminescence was measured, at 650nM by pho-
tomultiplier tube (PMT) built in the aggregometer, simul-
taneously with platelet aggregation.  
    Additional aliquots of citrated whole blood diluted in 
modified tyrode’s buffer were activated with 2 µg/mL 
collagen, and then incubated in the dark with monoclonal 
antibodies, phycoerythrin conjugated CD41 (Immunotech, 
Marseille; which was used to identify platelets because it 
has specificity for the glycoprotein IIb portion of the gly-
coprotein IIb-IIIa antigen present on resting and activated 
platelets), fluorescein isothiocyanate conjugated CD62p 
(Immunotech; an activation-dependent antibody directed 
against P-selectin, a component of the -granule mem-
brane of resting platelets that becomes expressed on the 
platelet surface membrane upon activation), or one of the 
isotype controls, immunoglobulin G1 (IgG1). Samples 
were fixed with paraformaldehyde to prevent artifactual 
in vitro platelet activation. Modified tyrode’s buffer ter-
minated the fixation, and samples were analysed on an 
EPICS Elite flow cytometer (Coulter Electronics) 
equipped with a 15-mW argon laser, at an excitation of 
488 nm. The fluorescence of fluorescein isothiocyanate 
and phycoerythrin was detected by using 525 nm and 575 
nm band pass filters respectively. Activated platelets were 
defined as CD41-positive events that expressed P-selectin. 
The data are reported as a proportion of maximum 
CD62P expression.  
 
Lipid screening and CRP Analysis. Lipids and CRP were 
analysed on the automated Olympus AU2700 biochemi-
cal analyser. The instrument was validated by calibrating 
and running controls for each parameter. Enzymatic col-
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orimetric methods were used for measuring total choles-
terol (based on cholesterol oxidase method), HDL choles-
terol (determined using anti human-beta-lipoprotein anti-
body binding to lipoproteins other than HDL) and triacyl-
glycerols (based on a method with glycerol blank). 
    LDL cholesterol was calculated, using following 
Friedwald formula15: 
LDL Cholesterol = Total cholesterol – [HDL Cholesterol 
+ VLDL],  
Where, VLDL = triacylglycerols/5 
    CRP was measured using immuno-turbidimetric 
method using anti-human CRP antibodies to form insolu-
ble aggregates.  
 
Serum alpha and gamma-tocopherol concentration. The 
Shimadzu HPLC system (Kyoto, Japan) used in this study 
consisted of a chromatograph LC-10AD and spectro-
fluorophotometer detector (RF-551) equipped with a 12 
µL LC flow cell. γ-Tocopherol, dl-α-Tocopherol and dl-
α-tocopheryl acetate were detected at excitation λ=298 
nm, emission λ=325 nm, recorded by a CR6A Chromato-
pac Recorder /Integrator. 
    For the analysis serum samples in ethanol (1:1) were 
treated with petroleum ether solvent (2:1) before a re-
versed-phase C-18 column, with a mobile phase of Ace-
tonitrile: Dichloromethane: Methanol (7:2:1), at a flow 
rate of 1.0 ml/min was employed. Quantitation of these 
compounds was achieved using linear calibration curves 
constructed from the peak area versus the concentration of 
the standard compound.  Before starting a sample run, 
external standards, followed by an internal QC (plasma 
frozen and allocated into multiple vials on day one from a 
normal subject) were checked.  
 
Statistical analysis  
Data are presented as means ± SDs. The data analyses 
were performed using a SPSS version 11.5 program 
(SPSS Corporation, Chicago IL, USA). Effects of differ-
ent Vitamin E (γ-tocopherol) doses (dose effect) on the 
parameters were analysed using GLM repeated measures 
of ANOVA adjusted for baseline values. Changes be-
tween pre- and post treatment in same dose (treatment 
effect) were using paired t-test. p values <0.05 were con-
sidered significant. 
 
RESULTS 
Compliance was good, as assessed by the number of pills 
returned and measure of serum α and γ-tocopherol 
 
Table 1.  Serum Gamma (γ-) tocopherol and alpha (α-) tocopherol 
 
 <5mg G-T (Placebo n=12) 
100mg G-T 
(n=14) 
200mg G-T 
(n=13) p-value* 
 Pre Post Pre Post Pre Post Treatment Dosage T*D
γ-
tocopherol 
(mg/mL) 
5.3±3.3 5.4±2.3   5.3±3.5b 16.8±7.2a  5.4±4.1b 30.1±20.7a 0.00 0.00 0.00
α-
tocopherol 
(mg/mL) 
26.7±5.6 26.7±5.0 24.9±8.2 22.4±5.4 22.8±7.5 24.1±9.8 0.94 0.25 0.31
 
Each parameter was analysed using GLM repeated measures of ANOVA; a,bSignificant difference within groups (Paired-Samples t-test). 
 
 
 
Table 2.  Platelet function tests 
 
 <5mg G-T (Placebo n=12) 
100mg G-T 
(n=14) 
200mg G-T 
(n=13) p-value* 
 Pre Post Pre Post Pre Post Treatment Dosage T*D 
P-selectin 
CD62p (%) 47.5±9.7 45.9±15.5 50.0±5.0
a 45.3±7.1b 47.1±8.0a 40.3±8.0b 0.03 0.32 0.57 
Agg/Slope 
(Ω/Sec) 0.22±0.05 0.21±0.07 0.25±0.08
a 0.22±0.06b 0.22±0.06 0.21±0.08 0.04 0.70 0.20 
ATP re-
lease 
(um) 
2.01±1.28 1.80±1.07 2.24±1.38 2.68±2.25 2.48±1.64 1.63±0.70 0.51 0.44 0.23 
Platelet 
(x109/L) 231±47 230±36 237±49 226±48 244±61 236±72 0.19 0.88 0.75 
MPV 
(fL) 8.35±0.69 8.09±0.70 8.62±0.95
a 8.35±0.75b 8.12±0.70 7.99±0.74 0.00 0.32 0.67 
 
Each parameter was analysed using GLM repeated measures of ANOVA; a,bSignificant difference within groups (Paired-Samples t-
test). 
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concentrations. No side effects from the active or placebo 
tablets were reported.  
    Baseline results for all groups were comparable. Five 
week of supplementation with 100 mg and 200 mg γ-T 
resulted in proportionately increased concentrations of 
serum γ-T (p<0.05). The serum level of α-tocopherol did 
not change after intervention in any group (Table 1). 
    There was a significant effect of γ-tocopherol treatment 
on platelet activation: p-selectin (CD62p%) decreased 
significantly after both doses (p<0.05), with little change 
after placebo (Table 2). 
    MPV decreased significantly with 100 mg γ-tocopherol 
treatment (p<0.05) but the decrease was not statistically 
significant for the higher dose. Platelet aggregation also 
decreased significantly with 100 mg γ-tocopherol (p<0.05) 
though little effect was seen with 200 mg γ-tocopherol or 
placebo (Table 2). 
    Gamma-tocopherol treatment resulted in a significant 
effect on LDL cholesterol. LDL cholesterol was signifi-
cantly decreased following 100 mg/d of γ-tocopherol 
supplementation (p<0.05) (Table 3).  
    HDL cholesterol increased significantly with 100 mg γ-
tocopherol and placebo. However a similar increase was 
not found with 200 mg γ-tocopherol suggesting the in-
crease is random and unlikely due to γ-tocopherol treat-
ment (Table 3) 
    Inflammation marker CRP did not decrease signifi-
cantly after supplementation with 200 mg γ-tocopherol. 
There were no significant changes in the serum levels of 
triacylglycerol, or in the whole blood platelet count and 
ATP release. 
 
DISCUSSION 
The potentially beneficial effects of vitamin E on cardio-
vascular disease (CVD) have been intensively investi-
gated in many interventional and epidemiological studies. 
However, most of these studies focused exclusively on α-
tocopherol and the protective effects of α-tocopherol sup-
plementation on CVD is equivocal.16, 17 Accordingly, we 
evaluated the effect of pure γ-tocopherol on platelet func-
tion, lipid concentrations and inflammation marker in 
blood. To the best of our knowledge, this is the first study 
that provides in vivo relationship between pure γ- 
tocopherol and thrombotic risk factors. 
    Specifically, the present study determined the effect of 
two doses of γ-T on platelet function, lipid profile and 
inflammation marker CRP in human subjects. We ob-
served a significant increase in serum γ-tocopherol con-
centrations after both doses. A significant decrease in 
platelet activity post 200 mg and 100 mg γ-tocopherol 
dose was also observed, though the changes between 
groups were not statistically significant. There was also a 
significant reduction in MPV, platelet aggregation and 
LDL cholesterol post 100 mg γ-tocopherol supplementa-
tion only.  
    Serum γ-tocopherol concentrations increased signifi-
cantly in all subjects in accordance with the concentration 
of dose, while no change was observed in serum α-
tocopherol concentrations. This suggests that any changes 
observed in this study in the platelet function and lipid 
profile would have been due to γ-tocopherol ingestion. 
    Several independent investigations have demonstrated 
that the blood concentration of γ-tocopherol, not α-
tocopherol, was negatively correlated to the incidence of 
coronary heart disease.18, 19 Gamma tocopherol is present 
in the diet at higher levels than α-tocopherol, but most 
studies show increased α-tocopherol in plasma. 5 Supple-
mentation with large amounts of α-tocopherol was shown 
to increase the breakdown and decrease blood concentra-
tions of γ-tocopherol, 11, 20 as a result of the function of 
the hepatic α-tocopherol transfer protein (α-TTP), which 
preferentially incorporates α-tocopherol into the plasma. 
10 Hosomi7 found that the biological activity of vitamin E 
analogs correlates to their affinity for α-TTP. Chopra and 
Bhagavan21 showed that bioavailability of both natural 
and synthetic α-tocopherol significantly suppresses the 
serum γ-tocopherol to the same extent.  
    Our results could explain the findings of previous epi-
demiological studies showing inverse correlation between 
vitamin E intake and incidence of CVD. It has been 
shown dietary source of vitamin E is much higher in γ-
tocopherol 5 compared to α-tocopherol, but all the inves-
tigational studies used very high concentration of α-
tocopherol, which could have broken down the γ-
tocopherol 11 and nullified the effect of vitamin E seen by 
previous studies. High dose of α-tocopherol reduces  
Table 3. Lipids and inflammation marker 
 
 <5mg G-T (Placebo n=12) 
100mg G-T 
(n=14) 
200mg G-T 
(n=13) p-value* 
 Pre Post Pre Post Pre Post 
Treat
ment Dosage T*D
Cholesterol 
(mmol/L) 4.9±0.9 5.1±1.0 4.9±1.1 4.6±0.8 5.1±1.2
 4.4±1.0 0.18 0.70 0.11
LDL 
(mmol/L) 2.8±0.6 2.9±0.7 3.0±1.0
a 2.6±0.8b 3.1±0.0 2.5±0.8 0.02 1.00 0.08
HDL 
(mmol/L) 1.5±0.4
 b 1.7±0.5a 1.3±0.4b 1.5±0.4a 1.3±0.5 1.4±0.4 0.00 0.41 0.06
Triacylglycerols 
(mmol/L) 1.4±0.9 1.1±0.6 1.1±0.3 1.0±0.4 1.3±0.6 1.2±0.6 0.12 0.62 0.71
C-reactive  
Protein (mg/L) 2.1±3.5 1.8±2.7 2.6±3.0 3.1±4.5 2.3±2.4
 1.9±1.7 0.65 0.67 0.15
 
Each parameter was analysed using GLM repeated measures of ANOVA.; a,bSignificant difference within groups (Paired-Samples t-test). 
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intestinal absorption, cell membrane transport and utilisa-
tion of other forms of vitamin E, especially γ-tocopherol. 
11,22,23 The hepatic α-TTP has the greatest affinity for α-
tocopherol compared to γ-tocopherol and is crucial for the 
relative percentage of transport of the various forms of 
vitamin E in the plasma lipoproteins. 5,7,23 This imbalance 
of α-tocopherol / γ-tocopherol levels in plasma may have 
significant health consequences. 7, 18  
    Liu, Saldeen and Li et al 12,13,24,25 have shown in vari-
ous animal and human studies that mixed tocopherols are 
more potent in preventing platelet aggregation and have 
stronger inhibitory effect on lipid per oxidation than α-
tocopherol alone. In the current study we used a pure 
form of γ-tocopherol and our results suggest that γ-
tocopherol supplementation had a direct positive effect on 
platelet activity and LDL cholesterol concentrations in 
blood of normal healthy people. 
    Circulating activated platelets are useful markers of 
local thrombotic events occurring in cardiovascular dis-
eases. We used flow cytometry to detect circulating acti-
vated platelets through expression of platelet surface gly-
coprotein, p-selectin, also known as CD62p. The p-
selectin, is rapidly translocated from α-granules inside the 
platelets to the cell surface on stimulation by physiologi-
cal agonists. During agonist-induced platelet activation, 
energy-dependent fusion of both alpha and dense granules 
with the plasma membrane permits expression of p-
selectin, which promote and propagate platelet adhesion 
to endothelial cells, neutrophils and monocytes.26  
    One possible mechanism by which γ-tocopherol might 
have reduced platelet activity (i.e. the reduced expression 
of p-selectin through decreased CD62p binding on plate-
let surface) could be related to platelet derived nitric ox-
ide (NO) bioactivity. Impaired platelet NO production 
and decreased bioavailability of NO have been associated 
with coronary disease states.27 Platelet-derived NO has 
been found to inhibit platelet aggregation and reduce 
platelet recruitment to a growing thrombus.28 α-
tocopherol might increase platelet NO release by its free 
radical scavenging activity and by preventing its quench-
ing by peroxyl radicals.29,30 One compensatory mecha-
nism is nitration of γ-tocopherol, through available nitra-
tion-prone positions on the chromanol ring of γ-
tocopherol .31,32 and thus depleting NO by reacting with it, 
which leads to an up-regulation of NO synthesis.28 
Freedman 30 suggested α-tocopherol might also be re-
sponsible in balancing NO and super oxide anion (SOD) 
in human platelets. Saldeen et al 13 suggested up-
regulation of SOD by both α-tocopherol and γ-tocopherol 
might be important mechanism for the effect of γ-
tocopherol on platelet aggregation, but they found γ-
tocopherol to be more potent than α-tocopherol in these 
effects. 
    A decrease in platelet activation could possibly be ex-
plained in terms of antioxidant effect of γ-tocopherol. 
Jiang et al 33-35 demonstrated cyclooxygenase-2 (COX-2) 
catalyses the synthesis of prostaglandins through oxida-
tion of arachidonic acid, which are important elements 
within the inflammatory process as well as platelet activa-
tion. They found COX-2 activity is inhibited by γ-
tocopherol but not by α-tocopherol.33-35 
    Significant decrease in LDL cholesterol is indicative of 
improved lipid profile, which may also explain the re-
duced platelet activity observed in this study. In recent in 
vitro studies, γ-tocopherol has been shown to inhibit lipid 
per oxidative damage 36 and to trap mutagenic electro-
philes 31 more efficiently than α-tocopherol. This finding 
supports our results demonstrating an improved lipid pro-
file and a trend of reduction in platelet activity post γ-
tocopherol supplementation. 
    Contrary to our findings, Jiang and Ames also provided 
strong evidence that γ-tocopherol shows anti-
inflammatory activities in vivo in rats.35 One of the rea-
sons for that could be that most of baseline results of CRP 
in this study were normal, around 2 mg/L and so there 
was not much scope for the values to further go down. It 
will be more realistic in future to evaluate the effect of γ-
tocopherol on populations with higher inflammatory con-
ditions. 
In conclusion, the results from the current study sug-
gest that the daily consumption of small amounts of γ-
tocopherol, in conjunction with usual dietary intake from 
mixed food sources may provide protection from oxida-
tive damage and prevent thrombosis. Further cellular re-
search would be valuable in helping to understand the 
mechanisms behind the biological effects of γ-tocopherol 
in higher risk populations such as diabetic subjects or 
those with known cardiovascular disease. Potential syner-
gistic effects between γ-tocopherol and other antioxidants 
and comparison with α-tocopherol supplementation could 
also be explored to clarify the role of γ-tocopherol in hu-
man health. 
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Gamma-生育醇的補充對血栓危險因子的影響 
 
目的：維生素 E的抗氧化活性主要衍生自 alpha-生育醇(α-T)及 gamma-生育醇 
(γ-T)。流行病學研究的結果指出維生素 E 的攝取與冠狀疾病為負相關。然
而，採用 α-T 的臨床試驗結果是可議的。我們評估每天補充 100 毫克或 200
毫克的 γ-T5週對血栓標記，例如：血小板活性、血脂及發炎標記 C反應蛋白
(CRP)的影響， 
方法及結果：採用雙盲平行研究設計，14名健康受試每天攝取 100毫克的 γ-
T，13名攝取 200毫克的 γ-T及 12名接受安慰劑(大豆膠囊加每天低於 5毫克
的 γ-T)。分析禁食前後血液樣本的劑量。血中 γ-T 上升濃度與介入期的劑量
呈現顯著相關(p<0.05)。接受有效成分的兩組，顯示補充之後血小板活性顯著
較低(p<0.05)。每天攝取 100毫克 γ-T的受試者，LDL膽固醇、血小板凝集及
平均血小板容積(MPV)顯著降低(p<0.05)。γ-T對其它的參數影響較小。 
結論：這些數據指出補充 γ-T 可能透過改善血脂及降低血小板活性，達到降
低血栓事件。 
 
關鍵字：gamma-生育醇、血小板、脂質、CRP、血小板危險因子。 
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